FOSAPREPITANT MSN (Accelagen Pty Ltd)
Product name
FOSAPREPITANT MSN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
Fosaprepitant dimeglumine
Registration type
New generic medicine
Indication
FOSAPREPITANT MSN, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:
- highly emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration)
- moderately emetogenic cancer chemotherapy (see Section 4.2 Dose and Method of Administration).